ALBERT

Description: The study tested the influence of prostaglandin E2 (PGE2) on the skeletal response to increased in vivo mechanical loading through a four-point bending device. One hundred and twenty Sprague-Dawley female rats (6 months old, 354 +/- 34 g) were divided into 12 groups to accommodate all possible combinations of doses of loads (25, 30, or 35 N) and PGE2 (0, 0.1, 0.3, or 1 mg/kg). Rats received subcutaneous injections of PGE2 daily and in vivo loading of the right tibia every Monday, Wednesday, and Friday for four weeks. Histomorphometric analysis of the periosteal and endocortical surfaces following in vivo dual fluorochrome labeling was performed on both the loaded region of the right tibial diaphysis and a similar region of the left tibial diaphysis. Without PGE2, the threshold for loading to stimulate bone formation was 30 N (peak strain 1360 mu epsilon) at the periosteal surface and 25 N (peak strain 580 mu epsilon) at the endocortical surface. Without loading, the minimum dose of PGE2 to stimulate bone formation at all surfaces was 1 mg/kg/day. When 1 mg/kg/day PGE2 was combined with the minimum effective load, an additive effect of PGE2 and loading on bone formation was observed at the endocortical surface, but a synergistic effect was noted at the periosteal surface. No combined effect of ineffective doses of loading and PGE2 was found. A synergistic effect at peak strains of approximately 1625 mu epsilon on the periosteal surface could suggest either the involvement of locally produced growth factors or autoregulation of endogenous synthesis of PGE2 by exogenously administered PGE2.

Description: CFD-based aeroelastic computations are performed to investigate the effect of nonlinear aerodynamics on transonic LCO (Limit Cycle Oscillations) characteristics of a two-dimensional supercritical wing with the NLR 7301section. It is found that the presentation of the viscous effects, including turbulence modeling, plays an important role on the accurate prediction of shock and LCO; and a small initial perturbation appears to produce large amplitude LCO at small mean pitch angle and plunge while a large amplitude initial perturbation produces small (or negligible) amplitude LCO at larger mean values. Also addressed in the paper is the issues related to multiblock MPI (Message Passing Interface) parallel computation.

Description: This experiment contains the crucial data for the lose, restore, and maintain (LRM) concept, a practical approach for reversing existing osteoporosis. The LRM concept uses anabolic agents to restore bone mass and architecture (+ phase) and then switches to an agent with the established ability to maintain bone mass, to keep the new bone (+/- phase). The purpose of this study was to learn whether switching to an agent known chiefly for its ability to maintain existing bone mass preserves new bone induced by PGE2 in osteopenic, estrogen-depleted rats. The current study had three phases, the bone loss (-), restore (+), and maintain (+/-) phases. We ovariectomized (OX) or sham ovariectomized (sham-OX) 5.5-month-old female rats (- phase). The OX rats were treated 5 months postovariectomy with 1-6 mg PGE2 per kg/day for 75 days to restore lost cancellous bone mass (+ phase), and then PGE2 treatment was stopped and treatment began with 1 or 5 micrograms/kg of risedronate, a bisphosphonate, twice a week for 60 days (+/- phase). During the loss (-) phase, the cancellous bone volume of the proximal tibial metaphysis in the OX rat fell to 19% of initial and 30% of age-matched control levels. During the restore (+) phase, the cancellous bone volume in OX rats doubled. When PGE2 treatment was stopped, however, and no special maintenance efforts were made during the maintain (+/-) phase, the PGE2-induced cancellous bone disappeared. In contrast, the PGE2-induced cancellous bone persisted when the PGE2 treatment was followed by either a 1 or 5 micrograms treatment of risedronate per kg given twice a week for 60 days during the maintain (+/-) phase. The tibial shaft demonstrated very little cortical bone loss during the loss (-) phase in OX rats. The tibial shaft cortical bone fell some 8%. During the restore (+) phase, new cortical bone in OX rats increased by 22%. When PGE2 treatment was stopped and nothing was given during the maintain (+/-) phase, however, all but the PGE2-induced subperiosteal bone disappeared. In contrast, when PGE2 treatment was stopped and 1 micron risedronate per kg twice a week for 60 days was administered during the maintenance (+/-) phase, the PGE2-induced subperiosteal bone and some of the subendocortical bone and marrow trabeculae persisted.(ABSTRACT TRUNCATED AT 400 WORDS).

Description: A series of 6-minute microgravity combustion experiments of opposed flow flame spread over thermally-thick PMMA has been conducted to extend data previously reported at high opposed flows to almost two decades lower in flow. The effect of flow velocity on flame spread shows a square root power law dependence rather than the linear dependence predicted by thermal theory. The experiments demonstrate that opposed flow flame spread is viable to very low velocities and more robust than expected from the numerical model, which predicts that at very low velocities (less than 5 centimeters per second), flame spread rates fall off more rapidly as flow is reduced. It is hypothesized that the enhanced flame spread observed in the experiments may be due to three- dimensional hydrodynamic effects, which are not included in the zero-gravity, two-dimensional hydrodynamic model. The effect of external irradiation was found to be more complex that the model predicted over the 0-2 Watts per square centimeter range. In the experiments, the flame compensated for the increased irradiation by stabilizing farther from the surface. A surface energy balance reveals that the imposed flux was at least partially offset by a reduced conductive flux from the increased standoff distance, so that the effect on flame spread was weaker than anticipated.

Description: For flames spreading into a low-velocity flow that can only be obtained in microgravity, we have observed behavior that is different from that which is obtained at higher velocities where radiative effects are unimportant and species transport is relatively fast. Unfortunately, lack of a large body of low-gravity flame spread experimental data inhibits progress in developing an understanding of the physics of low-velocity, opposed-flow flame spread phenomena. Recent DARTFire sounding rocket experimental studies though, coupled with developing theory and modelling, have allowed some strides in understanding to be made, on which we report here. Four launches to date have resulted in six experiments for opposed-flow flame spread over a thick PMMA sample. During the 6 min microgravity period, the PMMA samples were ignited, and steady flame spread was studied under varied flow velocity, oxidizer atmospheric conditions, and, because radiative heat transfer is so important in these slowly spreading flames, external radiant flux. These were the first attempts at such experimental control and measurement in microgravity. A recent reflight of the Solid Surface Combustion Experiment (SSCE) has demonstrated, as modelling predicts, that for the thick fuel of the DARTFire experiment, flame spread in a quiescent environment is a transient process evolving from ignition to extinction on the order of 600 s (Altenkirch et al., 1999). Further study then of the effects of radiation in the very low-velocity opposing flows is of interest in understanding the transition from steady, sustained spread to the unsteady evolution to extinction as the opposing flow is reduced further and eventually removed.

Description: In flame spreading in quiescent and low-velocity opposing flows, effects of surface reradiation and flame radiation are important in establishing the spread rate and whether the flame, once ignited, survives to steady spread or extinguishes after a time long compared to the ignition event. A reflight of the Solid Surface Combustion Experiment (SSCE), supported by modelling, demonstrates that for thick, flat fuels, the ultimate fate of the flame is extinction rather than steady spread. A mismatch between the thermal scale in the gas, driven by radiation, and the species diffusion scale, driven by mass diffusion, develops such that the high temperature regions of the flame are ultimately located in a region to which oxygen cannot be supplied at a sufficient rate to sustain reaction, and extinction occurs. Results of the experiment conducted on Space Shuttle mission STS 85 on 9 August 1997 are reviewed. For the flat surface geometry, while the hydrodynamic phenomena associated with opposed-flow flame spread may be treated two dimensionally, the radiative effects are three dimensional, and so modelling the radiative processes, with the mismatch in dimensionality, is difficult. The cylindrical geometry at least one long compared to the radius, provides a configuration in which the radiative processes for spread in the axial direction are two dimensional, thus simplifying the modelling. The cylindrical geometry allows for the development of more sophisticated radiative models without the complication of dimensionality concerns, e.g., discrete transfer, which is discussed in detail by Bundy (1998). Additionally, the cylindrical geometry results in a "focussing" of the heat transfer to the surface and may allow for steady spread for radii that for thick fuels of the same half-thickness there is no steady spread.

Description: This experiment contains the crucial data for the Lose, Restore and Maintain (LRM) concept, a practical approach for reversing existing osteoporosis. The LRM concept uses ovariectomy (ox) to lose bone, an anabolic agent to restore bone mass and then switches to an antiresorptive agent to maintain bone mass. We ox'd or sham-ox'd rats for 150 days (Loss Phase), treated them with 6 mg PGE(sub 2)kg/d for 75 days to restore lost cancellous bone mass (Restore Phase) and then stopped PGE(sub 2) treatment and began treatment with 1 or 5 micrograms/kg Risedronate, a bisphosphonate twice a week for 60 days (Maintain Phase). During the Loss Phase, cancellous bone volumes of the Proximal Tibial Metaphysis (PTM) in the ox'd rat fell to 19% of initial controls. During the Restore Phase, the PTM bone volume in ox'd rats doubled. However, when PGE(sub 2) treatment was stopped, the PGE(sub 2)-induced cancellous bone disappeared. In contrast, 5 miligrams of Risedronate inhibited the bone loss and maintained it at the PGE(sub 2) treatment level. The key dynamic histomorphometry value for the Restore (R) and Maintenance (M) phases was the ratio of bone formation to resorption rates. The ratio was elevated to 5.8 in the R phase and depressed to 0.4 for no and 1 miligram Risedronate treated M phase and to a ratio of near unity of 1.1 for the 5miligrams Risedronate treatment. These findings indicate that we were successful in maintaining the new PTM bone induced by PGE(sub 2) after discontinuing PGE(sub 2) by administering enough Risedronate, a resorption inhibitor. We concluded that the LRM concept is correct and such an approach should be considered when employing anabolic agents or growth factors in the treatment of osteoporosis. Continued use of an anabolic agent may not be appropriate because of cost, potential adverse side effects and a loss of efficacy.

Description: The object of this study was to determine whether prostaglandin E2 (PGE2) can prevent disuse (underloaded)-induced cortical bone loss as well as add extra bone to underloaded bones. Thirteen-month-old retired female Sprague-Dawley breeders served as controls or were subjected to simultaneous right hindlimb immobilization by bandaging and daily subcutaneous doses of 0, 1, 3, or 6 mg PGE2/kg/d for two and six weeks. Histomorphometric analyses were performed on double-fluorescent labeled undecalcified tibial shaft sections (proximal to the tibiofibular junction). Disuse-induced cortical bone loss occurred by enlarging the marrow cavity and increasing intracortical porosity. PGE2 treatment of disuse shafts further increased intracortical porosity above that in disuse alone controls. This bone loss was counteracted by enhancement of periosteal and corticoendosteal bone formation. Stimulation of periosteal and corticoendosteal bone formation slightly enlarged the total tissue (cross-sectional) area and inhibited marrow cavity enlargement. These PGE2-induced activities netted the same percentage of cortical bone with a different distribution than the beginning and age related controls. These findings indicate the PGE2-induced increase in bone formation compensated for the disuse and PGE2-induced bone loss, and thus prevented immobilization induced bone loss.

Description: This experiment contains the crucial data for the Lose, Restore and Maintain (LRM) concept, a practical approach for reversing existing osteoporosis. The LRM concept uses ovariectomy (ox) to lose bone, an anabolic agent to restore bone mass and then switches to an anti-resorptive agent to maintain bone mass. We ox'd or sham-ox'd rats for 150 days (Loss Phase), treated them with 6 mg PGE2/kg/d for 75 days to restore lost cancellous bone mass (Restore Phase) and then stopped PGE2 treatment and began treatment with 1 or 5 micro-g/kg Risedronate, a bisphosphonate twice a week for 60 days (Maintain Phase). During the Loss Phase, cancellous bone volumes of the proximal tibial metaphysis (PTM) in the ox'd rat fell to 19% of initial controls. During the Restore Phase, the PTM bone volume in ox'd rats doubled. However, when PGE2 treatment was stopped, the PGE2-induced cancellous bone disappeared. In contrast, 5 micro-g of Risedronate inhibited the bone loss and maintained it at the PGE2 treatment level. The key dynamic histomorphometry value for the restore (R) and maintenance (M) phases was the ratio of bone formation to resorption rates. The ratio was elevated to 5.8 in the R phase and depressed to 0.4 for no and 1 micro-g Risedronate treated M phase and to a ratio of near unity of 1.1 for the 5 micro-g Risedronate treatment. These findings indicate that we were successful in maintaining the new PTM bone induced by PGE2 after discontinuing PGE2 by administering enough Risedronate, a resorption inhibitor. We concluded that the LRM concept is correct and such an approach should be considered when employing anabolic agents or growth factors in the treatment of osteoporosis. Continued use of an anabolic agent may not be appropriate because of cost, potential adverse side effects and a loss of efficacy.